12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder

Neuropsychopharmacology

Volumn 39, Issue 6, 2014, Pages 1453-1459

  Grant, Paul J ^a   Joseph, Lisa A ^a   Farmer, Cristan A ^a   Luckenbaugh, David A ^a   Lougee, Lorraine C ^a   Zarate, Carlos A ^a   Swedo, Susan E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

clinical pharmacology clinical trials; mood anxiety stress disorders; obsessive compulsive disorder; psychiatry and behavioral sciences; psychopharmacology; riluzole

Indexed keywords

PLACEBO; RILUZOLE; PSYCHOTROPIC AGENT;

ADD ON THERAPY; ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTISM; CHILDREN GLOBAL ASSESSMENT SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DRUG COMBINATION; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOLOGICAL RATING SCALE;

ADOLESCENT; AGE OF ONSET; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; RILUZOLE; TREATMENT OUTCOME;

EID: 84900808494     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.343     Document Type: Article

References (32)

1. Abramowitz JS, Whiteside SR, Deacon BJ (2005). The effectiveness of treatment for pediatric obsessive-compulsive disorder: a meta-analysis. Behav Ther 36: 55-63. (Pubitemid 43150332)
2. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006). Glutamate transporter gene SLC1A1 associated with obsessivecompulsive disorder. Arch Gen Psychiatry 63: 769-776.
3. Bellingham MC (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17: 4-31.
4. Bodfish JW, Symons FJ, Parker DE, Lewis MH (2000). Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord 30: 237-243.
5. Cohen J (1988). Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum.
6. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M et al (2006). Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63: 778-785.
7. Farmer C, Thurm A, Grant P (2013). Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs 73: 303-314.
8. Geller DA (2006). Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatr Clin North Am 29: 353-370.
9. Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T et al (2003). Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 160: 1919-1928. (Pubitemid 39619624)
10. Grant P, Lougee L, Hirschtritt M, Swedo SE (2007). An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 17: 761-767. (Pubitemid 351158597)
11. Guy W (1976). ECDEU Assessment manual for psychopharmacology. In US Department of Health E, and Welfare (ed). National Institute of Mental Health: Rockville, MD.
12. Helsel WJ, Matson JL (1984). The assessment of depression in children: the internal structure of the Child Depression Inventory (CDI). Behav Res Ther 22: 289-298. (Pubitemid 14076174)
13. Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K et al (2011). Translating glutamate: from pathophysiology to treatment. Sci Transl Med 3: 102mr102.
14. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P et al (1997). Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADSPL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36: 980-988. (Pubitemid 27272932)
15. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO et al (2002). Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 41: 1431-1438. (Pubitemid 44698519)
16. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC et al (2000). The autism diagnostic observation schedulegeneric: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30: 205-223.
17. Lord C, Rutter M, Le Couteur A (1994). Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24: 659-685. (Pubitemid 24309810)
18. MacMaster FP, O'Neill J, Rosenberg DR (2008). Brain imaging in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 47: 1262-1272.
19. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH et al (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280: 1752-1756. (Pubitemid 28536875)
20. March JS, Parker JD, Sullivan K, Stallings P, Conners CK (1997). The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry 36: 554-565. (Pubitemid 27149194)
21. Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET (2008). Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 32: 525-549. (Pubitemid 351173336)
22. Micali N, Heyman I, Perez M, Hilton K, Nakatani E, Turner C et al (2010). Long-term outcomes of obsessive-compulsive disorder: follow-up of 142 children and adolescents. Br J Psychiatry 197: 128-134.
23. Pediatric OCD Treatment Study (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292: 1969-1976.
24. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G et al (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolescent Psychiatry 40: 222-229. (Pubitemid 32111026)
25. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000). Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39: 1096-1103.
26. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK et al (1997). Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36: 844-852. (Pubitemid 27250450)
27. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H et al (1983). A children's global assessment scale (CGAS). Arch Gen Psychiatry 40: 1228-1231. (Pubitemid 13015019)
28. Stewart SE, Geller DA, Jenike M, Pauls D, Shaw D, Mullin B et al (2004). Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatrica Scandinavica 110: 4-13. (Pubitemid 38822642)
29. Watson HJ, Rees CS (2008). Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry 49: 489-498. (Pubitemid 351503099)
30. Wink LK, Erickson CA, Stigler KA, McDougle CJ (2011). Riluzole in autistic disorder. J Child Adolesc Psychopharmacol 21: 375-379.
31. Wu K, Hanna GL, Rosenberg DR, Arnold PD (2012). The role of glutamate signaling in the pathogenesis and treatment of obsessivecompulsive disorder. Pharmacol Biochem Behav 100: 726-735.
32. Zarate CA, Manji HK (2008). Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol 4: 1223-1234.